Cancer Research Month: Research from Our Physicians
At Rush Radiosurgery, we’re proud of the contributions our dedicated physicians have made to the cancer care community. In two recent studies, Rush Radiosurgery radiation oncologist Dr. David Sher evaluated cost-effectiveness of stereotactic body radiation therapy (SBRT) with other cancer treatment procedures:
- Cost Effectiveness of SBRT v. Surgical Resection for Stage 1 Non-Small Cell Lung Cancer – This study examines the cost-effectiveness of treatment for stage I non-small cell lung cancer with stereotactic body radiation therapy (SBRT) versus traditional surgery. The study found that in a cost comparison, SBRT was nearly always the most cost-effective treatment strategy for patients who were marginally operable.
- Cost-Effectiveness Analysis of SBRT v. IMRT for Low-Risk Prostate Cancer – This study examines the cost-effectiveness of treatment for low-risk prostate cancer with SBRT versus the standard intensity-modulated radiation therapy (IMRT). The study concluded that SBRT contained more value than IMRT for external-beam treatment.
To learn more about Dr. Sher and his research, click here.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.